| First Author | Paynich ML | Year | 2017 |
| Journal | J Immunol | Volume | 198 |
| Issue | 7 | Pages | 2689-2698 |
| PubMed ID | 28202619 | Mgi Jnum | J:252836 |
| Mgi Id | MGI:5926568 | Doi | 10.4049/jimmunol.1601641 |
| Citation | Paynich ML, et al. (2017) Exopolysaccharide from Bacillus subtilis Induces Anti-Inflammatory M2 Macrophages That Prevent T Cell-Mediated Disease. J Immunol 198(7):2689-2698 |
| abstractText | Commensal bacteria contribute to immune homeostasis in the gastrointestinal tract; however, the underlying mechanisms for this are not well understood. A single dose of exopolysaccharide (EPS) from the probiotic spore-forming bacterium Bacillus subtilis protects mice from acute colitis induced by the enteric pathogen Citrobacter rodentium Adoptive transfer of macrophage-rich peritoneal cells from EPS-treated mice confers protection from disease to recipient mice. In vivo, EPS induces development of anti-inflammatory M2 macrophages in a TLR4-dependent manner, and these cells inhibit T cell activation in vitro and in C. rodentium-infected mice. In vitro, M2 macrophages inhibit CD4+ and CD8+ T cells. The inhibition of CD4+ T cells is dependent on TGF-beta, whereas inhibition of CD8+ T cells is dependent on TGF-beta and PD-L1. We suggest that administration of B. subtilis EPS can be used to broadly inhibit T cell activation and, thus, control T cell-mediated immune responses in numerous inflammatory diseases. |
